The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1300 participants.

Also called NCT04981327

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04981327
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT04981327. Randomized; single masking; primary purpose treatment. Start 2022-09-01 (anticipated); primary completion 2026-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
Acronym
API-CALF
Intervention (Drug)
Apixaban 2.5 MG Oral Tablet [ELIQUIS]
Lead sponsor
University Hospital, Geneva (class: other)
Collaborator
Sunnybrook Health Sciences Centre (class: other)

Record details

Record id
cardio:ct-nct04981327
Content hash
06723d8fb023b36753a682b09195e02cd248817179c76a6894815d65dfaa9d46